Focusing on Task of Reinventing Peptide Drugs Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides Warren P.Levy, Ph.D.
Peptides are among the most biologically relevant molecules known and also among the most productive areas of pharmaceutical R&...
Premium Company Profile Nastech Pharmaceutical - New Research Report on Companies and Markets Company-Profile/Premium-Comp ..Introduction Nastechs goal is to become a leader in both the development and commercialization of innovative, nasal drug delivery products and technologies, as well as in RNAi therapeutics.
Scope Contains...
Focusing on Task of Reinventing Peptide Drugs Unigene Has Introduced an Enzyme-Based Assay for the Discovery of Amidated Peptides Warren P.Levy, Ph.D.
Peptides are among the most biologically relevant molecules known and also among the most productive areas of pharmaceutical R&...
Experimental Agent Significantly Improves Migraine Pain, Symptoms June 30, 2008 (Boston, Massachusetts) An investigational oral migraine medication is effective in the treatment of acute moderate to severe attacks and associated symptoms without the direct vasoconstrictive effects typically associated with...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase - Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of...
Merck Stretching to New Day Highs on Migraine Treatment Study (MidnightTrader via COMTEX News Network) -- Merck (MRK) is soaring to new highs heading into the last hour of regular session trade, up 4.5% at 37.82, near its new day high of 37.88.The company announced earlier today that, in a Phase III...
Merck Stretching to New Day Highs on Migraine Treatment Study (MidnightTrader via COMTEX News Network) -- Merck (MRK) is soaring to new highs heading into the last hour of regular session trade, up 4.5% at 37.82, near its new day high of 37.88.The company announced earlier today that, in a Phase III...
::: Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in P Oral CGRP Receptor Antagonist Provided Similar Migraine Relief with Fewer Adverse Events Compared to Zolmitriptan BOSTON--(BUSINESS WIRE)--Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK...
Merck's (MRK) Investigational Migraine Treatment Improved Pain and Associated Symptoms in Phase III Study Merck (NYSE: MRK) announced that in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of migraine pain and...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase - Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase - Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved relief of...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain, Migraine-Associated Symptoms in Phase II (RTTNews) - Merck & Co.(MRK: News, Chart, Quote ) said that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide receptor antagonist, significantly improved...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase Merck&Co., (News/Aktienkurs) Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly improved...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase BOSTON--(BUSINESS WIRE)-- Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase BOSTON--(BUSINESS WIRE)--Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant (formerly MK-0974), its investigational oral calcitonin gene-related peptide (CGRP) receptor antagonist, significantly...
Merck's Investigational Migraine Treatment Telcagepant Improved Pain and Migraine-Associated Symptoms in Phase Author : MA-MERCK/TELCAGEPANT Category : Press Release News Alerts by Email ( click here ) Press Release News | Home BOSTON - (Business Wire) Merck & Co., Inc.today announced that, in a Phase III clinical trial, telcagepant ...
Merck Migraine Drug Comparable To AstraZeneca Drug In Study An experimental drug from Results of the Phase 3, or late-stage, trial were summarized in an abstract posted on the website of the American Headache Society.Full results will be presented at the society's annual meeting in Boston MK-0974...
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells - A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells - A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells PENZBERG, Germany - (Business Wire) A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin...
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.These...
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells PENZBERG, Germany--(BUSINESS WIRE)--A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin...
The xCELLigence System of Roche: A Different Way to Monitor GPCR Functions in Living Cells -A series of research studies have demonstrated the benefit of the xCELLigence System for functional screening of G-protein coupled receptors (GPCRs) activity, based on its ability to modulate the actin cytoskeleton and cell adhesion.
Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial Pivotal Trial in Medullary Thyroid Cancer Planned to Initiate This Summer SOUTH SAN FRANCISCO, Calif., June 16, 2008 /PRNewswire-FirstCall/ -- Exelixis, Inc.announced today that the company and the U.S.
Food and Drug Administration (FDA...
Exelixis, FDA Set SPA for XL184 Pivotal Study in Thyroid Cancer PM South San Francisco-based Exelixis Inc.reached an agreement with the FDA for a special protocol assessment for its pivotal Phase III trial of XL184, a small-molecule compound targeting MET, RET and VEGFR2, in medullary thyroid cancer....
